Tomoko Kagawa

Dr. Tomoko Kagawa


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YAYuichi Adachi
Yuichi Adachi
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
TKTakehiko Kobayashi
Takehiko Kobayashi
YKYu Kurahara
Yu Kurahara
SYShiomi Yoshida
Shiomi Yoshida
KSKatsuhiro Suzuki
Katsuhiro Suzuki

30 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TAToru Arai
Toru Arai
TTTakayuki Takimoto
Takayuki Takimoto
NTNaoko Takeuchi
Naoko Takeuchi
SMShojiro Minomo
Shojiro Minomo
TKTomoko Kagawa
Tomoko Kagawa
YIYoshikazu Inoue
Yoshikazu Inoue
Background: This study aimed to clarify the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). Methods: Eighty-six patients diagnosed with AE-IPF were included in this single-center retrospective study. The NLR was calculated by dividing the peripheral neutrophil count by the peripheral lymphocyte count. The cut-off values of the NLR for predicting 90-day survival were determined using receiver operating characteristic curve analysis. Oxygenation deterioration on days 4 and 8 relative to that on day 1 was clinically defined. The prognostic value of NLR was evaluated using Cox proportional hazard regression analysis. Results: The cut-off value of day-1, day-4, and day-8 NLRs for predicting 90-day survival was 12.13, 14.90, and 10.56, respectively. A higher day-1 NLR was a significant predictor of a poor prognosis in univariate and multivariate analyses. Survival was significantly better in patients without oxygenation deterioration on days 4 and 8 than in those with deterioration. Day-4 and day-8 NLR could predict 90-day survival in patients without oxygenation deterioration. Conclusions: Day-1 NLR was a useful predictor of 90-day survival in AE-IPF. Further, monitoring day-4 and day-8 NLRs and evaluating oxygenation deterioration may be useful for managing AE-IPF.

20 December 2021 in Canadian Respiratory Journal
Verified
Journal Article
Open access
TAToru Arai
Toru Arai
TKTomoko Kagawa
Tomoko Kagawa
YSYumiko Sasaki
Yumiko Sasaki
RSReiko Sugawara
Reiko Sugawara
CSChikatoshi Sugimoto
Chikatoshi Sugimoto
YIYoshikazu Inoue
Yoshikazu Inoue
Background. Hemosiderin-laden macrophages (HLMs) have been identified in the bronchoalveolar lavage fluid (BALF) of patients with idiopathic pulmonary fibrosis (IPF). This retrospective study examined the ability of HLMs in BALF to predict the acute exacerbation (AE) of chronic idiopathic interstitial pneumonias (IIPs). Methods. Two hundred and twenty-one patients with IIP diagnosed by bronchoscopy were enrolled in the study (IPF, n = 87; IIPs other than IPF, n = 134). Giemsa stain was used to detect HLMs in BALF specimens. Prussian blue stain was used to quantify HLMs in BALF, and a hemosiderin score (HS) was given to the specimens containing HLMs. Results. Twenty-four patients had a positive HS (range: 7‒132). The receiver-operating characteristic curve analysis identified the cutoff HS value for predicting the AE of IIPs to be 61.5. Seven cases had a higher HS (≥61.5) and 214 had a lower HS. AE occurred significantly earlier in the higher HS group (4/7 cases) than in the lower HS group (41/214 cases) during a median observation period of 1239 days (log-rank test, p = 0.026). Multivariate Cox proportional hazard regression analysis showed that a higher HS was a significant predictor of AE in addition to IPF, percent predicted forced vital capacity, and modified Medical Research Council score. The C-statistics for the prediction of AE did not significantly improve by all the above parameters with HS as compared without HS. Conclusions. A higher HS was a significant predictor of AE in IIPs but did not significantly improve the predictive ability of other parameters.

Verified
Journal Article
Open access
PDF file
TAToru Arai
Toru Arai
YKYu Kurahara
Yu Kurahara
MMMitsuhiro Moda
Mitsuhiro Moda
TKTakehiko Kobayashi
Takehiko Kobayashi
YMYoshinobu Matsuda
Yoshinobu Matsuda
YIYoshikazu Inoue
Yoshikazu Inoue
The prognosis of patients with coronavirus disease 2019 (COVID-19) and pre-existing interstitial lung disease (preILD) is poor, and no effective treatment strategy has been determined. The aim of this study was to assess the effectiveness of a steroid-based treatment strategy for patients with COVID-19 and preILD. We retrospectively reviewed the medical records of 610 consecutive patients with COVID-19 treated at our institution between 1 March 2020 and 30 October 2021 and identified 7 patients with preILD, all of whom were treated with corticosteroids and remdesivir. All the patients were men with a median age of 63 years. Three of four patients with severe disease required invasive positive-pressure ventilation (n = 2) or nasal high-flow therapy (n = 1). All three patients could be weaned from respiratory support; however, one died in hospital. The remaining patient with severe COVID-19 had a do-not-resuscitate order in place and died while hospitalized. All three patients with moderate COVID-19 were discharged. The 30-day mortality was 0%, and the mortality rate during the entire observation period was 28.5%. The prognosis of our patients with COVID-19 and preILD has been better than in previous reports. Our management strategy using corticosteroids may have improved these patients’ prognosis.

7 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TAToru Arai
Toru Arai
MHMasaki Hirose
Masaki Hirose
TKTomoko Kagawa
Tomoko Kagawa
NTNaoko Takeuchi
Naoko Takeuchi
TKTakehiko Kobayashi
Takehiko Kobayashi
YMYoshinobu Matsuda
Yoshinobu Matsuda
Background/Objectives: Idiopathic pulmonary fibrosis (IPF) is a fibrotic interstitial lung disease (ILD) with a poor prognosis. The prognosis of ILDs showing progressive pulmonary fibrosis (PPF) is poor, similar to that of IPF. Diarrhea is the most frequently observed adverse event in ILDs treated with nintedanib. Managing diarrhea is important for maintaining nintedanib use and improving the prognosis of ILDs. Methods: Between October 2022 and March 2025, we enrolled patients with severe nintedanib-induced diarrhea that was uncontrolled by loperamide and/or probiotics. Other drugs were administered to control diarrhea, and the patients were prospectively observed to evaluate stool frequency, stool form score (scores 3, 2, and 1 for watery stool, soft stool without form, and soft stool with form, respectively), quality of life (QOL) using the Japanese version of the irritable bowel syndrome (IBS)-QOL questionnaire, adverse events, and laboratory findings. Results: Eleven patients (IPF, n = 5; PPF, n = 6) were enrolled, and all patients were treated with ramosetron, a 5-hydroxytryptamine type 3 receptor (5-HT3) antagonist. Ramosetron was terminated within 3 weeks, before sufficient evaluation, because of insufficient efficacy (n = 1) and the discontinuation of nintedanib due to pneumothorax (n = 1). Stool frequency and stool form scores decreased significantly after the initiation of ramosetron therapy; however, IBS-QOL did not improve significantly. IBS-QOL correlated with shortness of breath scores but not with stool frequency. No prominent adverse events were associated with ramosetron administration. Conclusions: Ramosetron, a 5-HT3 antagonist, improved stool frequency and stool form in patients with severe nintedanib-induced diarrhea.

1 December 2020 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
YAYuichi Adachi
Yuichi Adachi
TTTakayuki Takimoto
Takayuki Takimoto
MTMaiko Takeda
Maiko Takeda
KMKinnosuke Matsumoto
Kinnosuke Matsumoto
NTNaoko Takeuchi
Naoko Takeuchi
YIYoshikazu Inoue
Yoshikazu Inoue
A 60-year-old man was admitted for ground glass opacity in the lower lung field and mediastinal lymphadenopathy. Blood tests revealed elevated serum IgM levels, and the urine test detected Bence-Jones protein. Surgical biopsy from the mediastinal lymph node and lung showed small lymphocytes and plasma cells between follicles, and AL kappa amyloid deposition. Genetic examination detected MYD88 L265P mutation. Our diagnosis was lymphoplasmacytic lymphoma (LPL), involving the mediastinum and the lung, followed by amyloidosis. Mutation analysis, in addition to conventional histological evaluation, was useful for a precise diagnosis.